PD1049 - REDUCING CATHETER-RELATED BLOODSTREAM INFECTIONS: EVALUATING THE INPATIENT USE OF TAUROLIDINE LOCK IN INTESTINAL FAILURE PATIENTS

Linked sessions

PD1049

REDUCING CATHETER-RELATED BLOODSTREAM INFECTIONS: EVALUATING THE INPATIENT USE OF TAUROLIDINE LOCK IN INTESTINAL FAILURE PATIENTS

N. Madrid1,*, J. Whiteside1, A. Bullivant1, F. Rahman1,2

1Princess Grace Hospital, 2University College Hospital NHS Foundation Trust, London, United Kingdom

 

Rationale: Catheter-related bloodstream infection (CRBSI) is a major complication in intestinal failure (IF) patients requiring parenteral nutrition (PN). Taurolidine lock (Taurolock™) is currently used in outpatient settings in the UK for home PN patients with previous episodes of CRBSI. This study evaluated the effectiveness of taurolidine lock in reducing the CRBSI rates for inpatients over a 2-year period in a private hospital in London.

Methods: A retrospective analysis was conducted over 2 years in IF patients receiving PN. The control group (n=41) had 664 catheter days and a CRBSI rate of 4.52 per 1000 catheter days, while the treatment group receiving taurolidine lock as inpatients while on PN (n=70) had 5,226 catheter days and a CRBSI rate of 0.19 per 1000 catheter days. An Exact Poisson Rate Ratio Test was used to compare CRBSI incidence rates, to account for differences in catheter exposure time and the small number of events.

Results: The treatment group experienced a 96.8% reduction in CRBSI rates compared to the control group, with a Rate Ratio of 0.031. This indicates that patients receiving taurolidine lock were significantly less likely to develop CRBSIs per 1000 catheter days than those in the control group. Given the substantial difference in catheter days between groups, Taurolock™’s effect remained consistent despite longer exposure durations in the treatment group. This reduction was statistically significant (p<0.05), indicating a substantial decrease in CRBSI incidence with the treatment.

Conclusion: The use of taurolidine lock significantly reduced CRBSI rates in IF patients over a 2-year period, suggesting its potential as a preventive strategy. These findings support the integration of the treatment into clinical practice to improve patient outcomes. Further studies with larger cohorts are recommended to confirm these results and assess long-term efficacy.

Disclosure of Interest: None declared